Choices, persistence and adherence to antihypertensive agents: Evidence from RAMQ data

Canadian Journal of Cardiology

Volumn 24, Issue 4, 2008, Pages 269-273

  Lachaine, Jean ^a   Petrella, Robert J ^b   Merikle, Elizabeth ^c   Ali, Farzad ^c  

^a UNIVERSITÉ DE MONTRÉAL   (Canada)

^b UNIVERSITY OF WESTERN ONTARIO   (Canada)

^c PFIZER INC   (United States)

Author keywords

Compliance; Hypertension; Population health

Indexed keywords

ACEBUTOLOL; AMILORIDE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; ATENOLOL; BENAZEPRIL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; CALCIUM CHANNEL BLOCKING AGENT; CAPTOPRIL; CILAZAPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRIL; ETACRYNIC ACID; FOSINOPRIL; FUROSEMIDE; HYDROCHLOROTHIAZIDE; INDAPAMIDE; LABETALOL; METOLAZONE; METOPROLOL; NADOLOL; OXPRENOLOL; PINDOLOL; PROPRANOLOL; SOTALOL; SPIRONOLACTONE; TIMOLOL; UNINDEXED DRUG;

ADULT; AGED; ANTIHYPERTENSIVE THERAPY; ARTICLE; CANADA; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG CHOICE; EVIDENCE BASED MEDICINE; FEMALE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; PATIENT COMPLIANCE; RANDOM SAMPLE; REIMBURSEMENT; TREATMENT OUTCOME; HEALTH CARE QUALITY; HEALTH SURVEY; INSURANCE; MIDDLE AGED; PUBLIC HEALTH; STATISTICS;

ADRENERGIC BETA-ANTAGONISTS; ADULT; AGED; AGED, 80 AND OVER; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; CALCIUM CHANNEL BLOCKERS; DIURETICS; FEMALE; HEALTH SURVEYS; HUMANS; HYPERTENSION; INSURANCE COVERAGE; MALE; MIDDLE AGED; NATIONAL HEALTH PROGRAMS; PATIENT COMPLIANCE; QUALITY ASSURANCE, HEALTH CARE; QUEBEC;

EID: 42949083831     PISSN: 0828282X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0828-282X(08)70175-2     Document Type: Article

References (40)

1. Wolf-Maier K, Cooper RS, Banegas JR, et al. Hypertension prevalence and blood pressure levels in 6 European countries, Canada and the United States. JAMA 2003;289:2363-9.
2. Berenson GS, Srinivasan SR, Bao W, Newman WP III, Tracy RE, Wattigney WA. Association between multiple cardiovascular risk factors and atherosclerosis in children and young adults. The Bogalusa Heart Study. N Engl J Med 1998;338:1650-6.
3. Thompson DW, Furlan AJ. Clinical epidemiology of stroke. Neurol Clin 1996;14:309-15.
4. Murray CJ, Lopez AD. Evidence based health policy - lessons from the Global Burden of Disease Study. Science 1996;274:740-3.
5. Murray CJ, Lopez AD. Global mortality, disability and the contribution of risk factors: Global Burden of Disease Study. Lancet 1997;349:1436-46.
6. IMS Health, Canadian Disease and Therapeutic Index (CDTI), 2004
7. Vasan RS, Beiser A, Seshadri S, Larson MG, Kannel WB, D'Agostino RB, Levy D. Residual lifetime risk for developing hypertension in middle-aged women and men: The Framingham Heart Sludy. JAMA. 2002 Feb 27;287(8):1003-10.
8. Joffres MR, Ghadirian P, Fodor JG, et al. Awareness, treatment and control of hypertension in Canada. Am J Hypertens 1997;10:1097-102
9. Hemmelgarn BR, Zarnke KB, Campbell NR, et al; Canadian Hypertension Education Program, Evidence-Based Recommendations Taskforce. The 2004 Canadian Hypertension Education Program recommendations for the management of hypertension: Part I. Blood pressure measurement, diagnosis and assessment of risk. Can J Cardiol 2004;20:31-40.
10. Khan NA, McAlister FA, Campbell NR, et al; Canadian Hypertension Education Program. The 2004 Canadian recommendations for the management of hypertension: Part II-Therapy. Can J Cardiol 2004;20:41-54.
11. Touyz RM, Campbell N, Logan A, Gledhill N, Petrella R, Padwal R; Canadian Hypertension Education Program. The 2004 Canadian recommendations for the management of hypertension: Part III-Lifestyle modifications to prevent and control hypertension. Can J Cardiol 2004;20:55-9.
12. The ALLHAT Collaborative Research Group. Major outcomes in high risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002;288:2981-97. (Errata in 2003;289:178; 2004;291:2196.)
13. Dahlof B, Devereux RB, Kjeldsen SE, et al; for the LIFE study group. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): A randomized trial against atenolol. Lancet 2001;359:995-1003.
14. Wing LM, Reid CM, Ryan P, et al. Second Australian National Blood Pressure Study (ANBP2). Australian Comparative Outcome Trial of ACE inhibitor- and diuretic-based treatment of hypertension in the elderly. Management Committee on behalf of the High Blood Pressure Research Council of Australia. Clin Exper Hypertens 1997;19:779-91.
15. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000;342:145-53. (Errata in 20004;342:1376; 2000;342:748.)
16. Birnbaum HG, Cremieux PY, Greenberg PE, LeLorier J, Ostrander JA, Venditti L. Using healthcare claims data for outcomes research and pharmacoeconomic analyses. Pharmacoeconomics 1999;16:1-8.
17. Cardinal H, Monfared AA, Dorais M, Lelorier J. A comparison between persistence to therapy in ALLHAT and in everyday clinical practice: A generalizability issue. Can J Cardiol 2004;20:417-21.
18. Caro JJ, Speckman JL, Salas M, Raggio G, Jackson JD. Effect of initial drug choice on persistence with antihypertensive therapy: The importance of actual practice data. CMAJ 1999;160:41-6.
19. Von Korff M, Wagner EH, Saunders K. A chronic disease score from automated pharmacy data. J Clin Epidemiol 1992;45:197-203.
20. Bourgault C, Rainville B, Suissa S. Antihypertensive drug therapy in Saskatchewan: Patterns of use and detertminants in hypertension. Arch Intern Med 2001;161:1873-9.
21. Sheehy O, LeLorier J. Patterns of amlodipine and felodipine use in an elderly Quebec population. Can J Cardiol 2000;16:1109-17.
22. Morningstar BA, Sketris IS, Kephart GC, Sclar DA. Variation in pharmacy prescription refill adherence measures by type of oral antihyperglycaemic drug therapy in seniors in Nova Scotia, Canada. J Clin Pharm Ther 2002;27:213-20.
23. Hill MN. Adherence to antihypertensive therapy. In Izzo JL, Black HR, eds. Hypertension Primer Dallas, 2nd edn. Texas: American Heart Association, 1999:348-51.
24. Institute of Health Economics. Hypertension and economic burden of illness in Canada Report submitted to the Laboratory for Disease Control. June 2000.
25. Paramore LC, Halpern MT, lapuerta P, et al. Impact of poorly controlled hypertension on healthcare resource utilization and cost. Am J Manag Care 2001;7:389-98.
26. Rizzo JA, Simons WR. Variations in compliance among hypertensive patients by drug class: Implications for health care costs. Clin Ther 1997;19:1446-57.
27. McCombs JS, Nichol MB, Newman CM, Sclar DA. The costs of interrupting antihypertensive drug therapy in a Medicaid population. Med Care 1994;32:214-26.
28. Caro JJ, Speckman JL. Existing treatment strategies: Does noncompliance make a difference? J Hypertens Suppl 1998;16:S31-4.
29. Marentette MA, Gerth WC, Billings OK, Zarnke KB. Antihypertensive therapy persistence and drug class. Can J Cardiol 2002;18:649-56.
30. Caro JJ, Salas M, Speckman JL, Raggio G, Jackson JD. Persistence with treatment for hypertension in actual practice. CMAJ 1999;160:31-7.
31. Perreault S, Lamarre D, Blais L, et al. Persistence with treatment in newly treated middle-aged patients with essential hypertension. Ann Pharmacother 2005;39:1401-8.
32. McCombs JS, Nichol MB, Newman CM, Sclar DA. The costs of interrupting antihypertensive drug therapy in a Medicaid population. Med Care 1994; 32:214-26.
33. Bloom B. Continuation of initial antihypertensive mediction after 1 year of therapy. Clin Ther 1998;20:671-81.
34. Lopatriello S, Berto P, Cramer J, Bustacchini S, Ruffo P. Different aspects of adherence to antihypertensive treatments. Expert Rev Pharmacoeconomics Outcomes Res 2004;4:317-33.
35. Marentette MA, Gerth WC, Billings DK, Zarnke KB. Antihypertensive persistence and drug class. Can J Cardiol 2002;18:649-56.
36. Morgan SG, Yan L. Persistence with hypertension treatment among community-dwelling BC seniors. Can J Clin Pharmacal 2004;11:e267-e273.
37. Hamilton GA. Measuring adherence in a hypertension clinical trial. Eur J Cardiovasc Nurs 2003;2:219-28.
38. Chapman RH, Benner JS, Petrilla AA, et al. Predictors of adherence with antihypertensive and lipid-lowering therapy. Arch Intern Med 2005;165:1147-52.
39. Wang PS, Benner JS, Glynn RJ, Winkelmayer WC, Mogun H, Avorn J. How well do patients report noncompliance with antihypertensive medications?: A comperison of self-report versus filled prescriptions. Pharmacoepidemiol Drug Saf 2004;13:11-9.
40. Schectman JM, Bovbjerg VE, Voss JO. Predictors of medication-refill adherence in an indigent rural population. Med Care 2002;40:1294-300.